An Open Label Study of Levetiracetam Monotherapy in Japanese Patients With Newly Diagnosed Focal Epilepsy

Registry ID

EUCTR2014-004377-16

Source registry

EUCTR

Phase

PHASE3

Sponsor

UCB Japan Co. Ltd.

Last update

2026-08-16

Conditions

• Focal Epilepsy

Summary

The primary objective of this study is to evaluate the efficacy of LEV used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly or recently diagnosed epilepsy subjects.

Related clinical trials

• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
• High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT
• An Open-label Study of XEN1101 in Epilepsy
• Sleep Architecture & Cognition in Focal Epilepsy
• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

View on source registry